Ethic Inc. Has $651,000 Position in Repligen Corporation $RGEN

Ethic Inc. raised its stake in Repligen Corporation (NASDAQ:RGEN) by 195.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 5,065 shares of the biotechnology company’s stock after acquiring an additional 3,353 shares during the period. Ethic Inc.’s holdings in Repligen were worth $651,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Canada Pension Plan Investment Board bought a new stake in shares of Repligen in the fourth quarter worth $792,000. CANADA LIFE ASSURANCE Co grew its stake in shares of Repligen by 17.7% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 41,175 shares of the biotechnology company’s stock valued at $5,924,000 after acquiring an additional 6,200 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Repligen by 28.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 580,485 shares of the biotechnology company’s stock valued at $83,556,000 after acquiring an additional 126,913 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Repligen by 8.9% in the fourth quarter. MetLife Investment Management LLC now owns 29,774 shares of the biotechnology company’s stock valued at $4,286,000 after acquiring an additional 2,428 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Repligen by 89.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,718 shares of the biotechnology company’s stock worth $967,000 after purchasing an additional 3,167 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on RGEN shares. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Sunday, June 29th. Barclays started coverage on shares of Repligen in a report on Tuesday, June 24th. They issued an “overweight” rating and a $150.00 target price for the company. Wells Fargo & Company dropped their target price on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, July 30th. Royal Bank Of Canada increased their target price on shares of Repligen from $193.00 to $204.00 and gave the stock an “outperform” rating in a report on Wednesday, July 30th. Finally, Evercore ISI dropped their target price on shares of Repligen from $140.00 to $130.00 and set an “in-line” rating for the company in a report on Tuesday, July 8th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average price target of $169.45.

Repligen Stock Performance

NASDAQ:RGEN opened at $121.56 on Thursday. The company has a market capitalization of $6.84 billion, a PE ratio of -486.22, a P/E/G ratio of 2.27 and a beta of 1.05. The company has a 50 day simple moving average of $121.95 and a two-hundred day simple moving average of $132.06. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Martin D. Madaus bought 1,800 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director owned 1,800 shares of the company’s stock, valued at $201,834. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.